The Walt lab pioneered the microwell array-based platforms for ultrasensitive biomarker detection and is now working towards new diagnostic approaches and translating them into products that can non-invasively and more accurately diagnose and assess the states of certain forms of cancer, infectious and neurodegenerative diseases. The technique, known as Single Molecule Arrays (Simoa), utilizes a novel digital readout method and can be used to detect proteins, post-translational modifications, microRNAs and biologically relevant small molecules. Most importantly, Simoa has the ability to improve the limit of detection of conventional enzyme-linked immunosorbent assay (ELISA) by 100-1000 fold. This increased sensitivity is critical for early disease diagnostics and for detecting differences between patients and healthy subjects that may be unobservable by other technologies.
Please refer to the Research page for a detailed list of ongoing projects.
2019/01: Dr. Walt is to be inducted into the National Inventors Hall of Fame at CES as an “innovation game-changer who has transformed our world”!
2019/01: Limor, Alissa and Stacy’s work on “Impact of clinical sample handling and processing on ultra-low level measurements of plasma cytokines” was published on Clinical Biochemistry!
2018/12: Xu and Limor’s work on “Competitive Immunoassays for the Detection of Small Molecules Using Single Molecule Arrays” was published on Journal of the American Chemical Society!
2018/11: In collaboration with Prof. George Church’s group (Wyss Institute) and Prof. Alice Chen-Plotkin (University of Pennsylvania), our lab received a grant from Chan Zuckerberg Initiative to enable better diagnosis and monitoring of Parkinson’s disease.